TransMedics Group (NASDAQ:TMDX) Trading 2.8% Higher

Shares of TransMedics Group, Inc. (NASDAQ:TMDX) traded up 2.8% during mid-day trading on Monday . The stock traded as high as $147.44 and last traded at $146.00. 96,134 shares were traded during trading, a decline of 87% from the average session volume of 757,982 shares. The stock had previously closed at $142.01.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. TD Cowen lifted their price target on TransMedics Group from $130.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, June 7th. Morgan Stanley lifted their price target on TransMedics Group from $75.00 to $95.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 28th. Oppenheimer lifted their price target on TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a research report on Wednesday, May 1st. Cantor Fitzgerald assumed coverage on TransMedics Group in a research report on Thursday, June 6th. They set an “overweight” rating and a $161.00 price target on the stock. Finally, Stephens assumed coverage on TransMedics Group in a research report on Tuesday, June 4th. They set an “overweight” rating and a $151.00 price target on the stock. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, TransMedics Group currently has an average rating of “Moderate Buy” and a consensus price target of $133.88.

TransMedics Group Trading Up 2.0 %

The company has a 50-day moving average price of $122.35 and a 200 day moving average price of $95.59. The company has a quick ratio of 8.76, a current ratio of 9.72 and a debt-to-equity ratio of 3.18. The firm has a market cap of $4.81 billion, a price-to-earnings ratio of -429.29 and a beta of 1.95.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.40. The company had revenue of $96.90 million for the quarter, compared to analyst estimates of $83.78 million. TransMedics Group had a positive return on equity of 7.95% and a negative net margin of 3.43%. The business’s revenue was up 132.9% compared to the same quarter last year. During the same period last year, the company earned ($0.08) earnings per share. As a group, research analysts anticipate that TransMedics Group, Inc. will post 0.77 earnings per share for the current fiscal year.

Insider Transactions at TransMedics Group

In related news, insider Tamer I. Khayal sold 4,947 shares of the business’s stock in a transaction dated Thursday, April 4th. The stock was sold at an average price of $80.36, for a total transaction of $397,540.92. Following the transaction, the insider now directly owns 25,185 shares in the company, valued at $2,023,866.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other TransMedics Group news, CEO Waleed H. Hassanein sold 8,625 shares of TransMedics Group stock in a transaction that occurred on Friday, June 14th. The stock was sold at an average price of $141.85, for a total transaction of $1,223,456.25. Following the sale, the chief executive officer now directly owns 61,643 shares of the company’s stock, valued at $8,744,059.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Tamer I. Khayal sold 4,947 shares of the business’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $80.36, for a total value of $397,540.92. Following the completion of the transaction, the insider now directly owns 25,185 shares in the company, valued at $2,023,866.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 290,501 shares of company stock worth $33,268,189. Company insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its holdings in shares of TransMedics Group by 1.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,814,442 shares of the company’s stock worth $99,341,000 after acquiring an additional 29,798 shares in the last quarter. Moody Aldrich Partners LLC raised its position in TransMedics Group by 110.3% in the 4th quarter. Moody Aldrich Partners LLC now owns 46,312 shares of the company’s stock worth $3,655,000 after purchasing an additional 24,290 shares during the last quarter. American Century Companies Inc. raised its position in TransMedics Group by 271.2% in the 3rd quarter. American Century Companies Inc. now owns 486,956 shares of the company’s stock worth $26,661,000 after purchasing an additional 355,755 shares during the last quarter. Alpha DNA Investment Management LLC bought a new position in TransMedics Group in the 4th quarter worth approximately $500,000. Finally, Qube Research & Technologies Ltd raised its position in TransMedics Group by 31.2% in the 3rd quarter. Qube Research & Technologies Ltd now owns 84,450 shares of the company’s stock worth $4,624,000 after purchasing an additional 20,081 shares during the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.